Clinical trial
Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent…
NCT00002572 · University of Colorado, Denver, Other · Completed
Key facts
| NCT number | NCT00002572 |
|---|---|
| Title | Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors |
| Official title | Intracavitary Allogenic Cytotoxic T Lymphocytes and Human Recombinant Interleukin-2 Therapy for Recurrent Primary Brain Tumors |
| Lead sponsor | University of Colorado, Denver, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological, Procedure |
| Interventions | aldesleukin, muromonab-CD3, therapeutic tumor infiltrating lymphocytes, conventional surgery |
| Enrollment | 10 |
| Start date | Nov 1, 1994 |
| Primary completion | Dec 1, 1999 |
| Completion | Dec 1, 1999 |
| First posted | Jul 29, 2004 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: